1
|
Demicheli C, Vallejos VMR, Lanza JS, Ramos GS, Do Prado BR, Pomel S, Loiseau PM, Frézard F. Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis. Biophys Rev 2023; 15:751-765. [PMID: 37681109 PMCID: PMC10480371 DOI: 10.1007/s12551-023-01073-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 05/30/2023] [Indexed: 09/09/2023] Open
Abstract
The pentavalent meglumine antimoniate (MA) is still a first-line drug in the treatment of leishmaniasis in several countries. As an attempt to elucidate its mechanism of action and develop new antimonial drugs with improved therapeutic profile, Sb(V) complexes with different ligands, including β-cyclodextrin (β-CD), nucleosides and non-ionic surfactants, have been studied. Interestingly, Sb(V) oxide, MA, its complex with β-CD, Sb(V)-guanosine complex and amphiphilic Sb(V) complexes with N-alkyl-N-methylglucamide, have shown marked tendency to self-assemble in aqueous solutions, forming nanoaggregates, hydrogel or micelle-like nanoparticles. Surprisingly, the resulting assemblies presented in most cases slow dissociation kinetics upon dilution and a strong influence of pH, which impacted on their pharmacokinetic and therapeutic properties against leishmaniasis. To explain this unique property, we raised the hypothesis that multiple pnictogen bonds could contribute to the formation of these assemblies and their kinetic of dissociation. The present article reviews our current knowledge on the structural organization and physicochemical characteristics of Sb-based supramolecular assemblies, as well as their pharmacological properties and potential for treatment of leishmaniasis. This review supports the feasibility of the rational design of new Sb(V) complexes with supramolecular assemblies for the safe and effective treatment of leishmaniasis.
Collapse
Affiliation(s)
- Cynthia Demicheli
- Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Virgínia M. R. Vallejos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | | | - Guilherme S. Ramos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Bruno R. Do Prado
- Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Sébastien Pomel
- Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France
| | - Philippe M. Loiseau
- Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France
| | - Frédéric Frézard
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| |
Collapse
|
2
|
Cosco D, Bruno F, Castelli G, Puleio R, Bonacci S, Procopio A, Britti D, Fresta M, Vitale F, Paolino D. Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. Macromol Biosci 2021; 21:e2100046. [PMID: 34117834 DOI: 10.1002/mabi.202100046] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 04/26/2021] [Indexed: 11/08/2022]
Abstract
Leishmaniasis is a human and animal disease endemic in tropical and subtropical areas treated by means of pentavalent antimony as first-line approach. Unfortunately, the formulations available on the market are characterized by significant side effects and a total remission of the disease is difficult to be obtained. The aim of this investigation is to describe the development and characterization of aqueous-core poly-l-lactide (PLA) nanocapsules containing glucantime (meglumine antimoniate, MA) with the aim of increasing the pharmacological efficacy of the active compound. The polymeric systems characterized by a mean diameter of ≈300 nm exert a great interaction with murine macrophages. MA-loaded PLA nanocapsules show a great antileishmanial activity on mice infected with Leishmania infantum with respect to the free drug, favoring a decrease of the administration times. The biodistribution profiles demonstrate a lower renal accumulation of MA after its nanoencapsulation and a significant increase of its plasmatic half-life. The parasite load evaluated by immunohistochemistry shows a significant decrease in liver, spleen, and kidneys when mice are treated with MA-loaded PLA nanocapsules especially after 45 days. The obtained results demonstrate the potential application of MA-loaded PLA nanocapsules as novel nanomedicine for the treatment of leishmaniasis.
Collapse
Affiliation(s)
- Donato Cosco
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Federica Bruno
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Germano Castelli
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Roberto Puleio
- Laboratorio Istopatologia e Immunoistochimica, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Sonia Bonacci
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Antonio Procopio
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Domenico Britti
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Massimo Fresta
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Fabrizio Vitale
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Donatella Paolino
- Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| |
Collapse
|
3
|
Bruni N, Stella B, Giraudo L, Della Pepa C, Gastaldi D, Dosio F. Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine 2017; 12:5289-5311. [PMID: 28794624 PMCID: PMC5536235 DOI: 10.2147/ijn.s140363] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania, which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.
Collapse
Affiliation(s)
| | - Barbara Stella
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| | | | - Carlo Della Pepa
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| | - Daniela Gastaldi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| |
Collapse
|
4
|
Ferreira WA, Islam A, Andrade APS, Fernandes FR, Frézard F, Demicheli C. Mixed antimony(V) complexes with different sugars to modulate the oral bioavailability of pentavalent antimonial drugs. Molecules 2014; 19:5478-89. [PMID: 24786687 PMCID: PMC6270655 DOI: 10.3390/molecules19055478] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 04/15/2014] [Accepted: 04/24/2014] [Indexed: 11/16/2022] Open
Abstract
Previous studies have shown that the association of the drug meglumine antimoniate (MA) with β-cyclodextrin can improve its bioavailability by the oral route. In this work, ribose and maltose were investigated for their ability to form mixed or association complexes with MA, release MA and modulate the serum levels of Sb after oral administration in mice. Analysis of the MA/ribose composition by high performance liquid chromatography coupled to mass spectrometry (LCMS-IT-TOF) revealed the presence of mixed meglumine-Sb-ribose and Sb-ribose complexes. Analysis of the MA/maltose composition suggested the formation of MA-maltose association compounds. Circular dichroism characterization of these compositions following dilution in water at 37 °C suggested a partial and slow dissociation of the association compounds. When the MA/ribose composition was administered orally and compared to MA, the serum concentration of Sb was significantly lower after 1 h and greater after 3 h. On the other hand, the MA/maltose composition showed similar serum Sb concentration after 1 h and higher level of Sb after 3 h, when compared to MA. In conclusion, the present study has demonstrated the formation of mixed or association complexes of MA with sugars, such as maltose and ribose, which promoted sustained serum level of Sb after oral administration.
Collapse
Affiliation(s)
- Weverson A Ferreira
- Department of Chemistry, Institute of Exact Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
| | - Arshad Islam
- Department of Chemistry, Institute of Exact Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
| | - Aretha Priscilla S Andrade
- Department of Chemistry, Institute of Exact Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
| | - Flaviana R Fernandes
- Department of Physiology and Biophysics, Institute of Biological Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
| | - Frédéric Frézard
- Department of Physiology and Biophysics, Institute of Biological Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
| | - Cynthia Demicheli
- Department of Chemistry, Institute of Exact Sciences - Federal University of Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil.
| |
Collapse
|
5
|
Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis. Antimicrob Agents Chemother 2013; 57:4229-4236. [PMID: 23796930 DOI: 10.1128/aac.00639-13] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Accepted: 06/13/2013] [Indexed: 12/24/2022] Open
Abstract
The need for daily parenteral administration is an important limitation in the clinical use of pentavalent antimonial drugs against leishmaniasis. In this study, amphiphilic antimony(V) complexes were prepared from alkylmethylglucamides (L8 and L10, with carbon chain lengths of 8 and 10, respectively), and their potential for the oral treatment of visceral leishmaniasis (VL) was evaluated. Complexes of Sb and ligand at 1:3 (SbL8 and SbL10) were obtained from the reaction of antimony(V) with L8 and L10, as evidenced by elemental and electrospray ionization-tandem mass spectrometry (ESI-MS) analyses. Fluorescence probing of hydrophobic environment and negative-staining transmission electron microscopy showed that SbL8 forms kinetically stabilized nanoassemblies in water. Pharmacokinetic studies with mice in which the compound was administered by the oral route at 200 mg of Sb/kg of body weight indicated that the SbL8 complex promoted greater and more sustained Sb levels in serum and liver than the levels obtained for the conventional antimonial drug meglumine antimoniate (Glucantime [Glu]). The efficacy of SbL8 and SbL10 administered by the oral route was evaluated in BALB/c mice infected with Leishmania infantum after a daily dose of 200 mg of Sb/kg for 20 days. Both complexes promoted significant reduction in the liver and spleen parasite burdens in relation to those in the saline-treated control group. The extent of parasite suppression (>99.96%) was similar to that achieved after Glu given intraperitoneally at 80 mg of Sb/kg/day. As expected, there was no significant reduction in the parasitic load in the group treated orally with Glu at 200 mg of Sb/(kg day). In conclusion, amphiphilic antimony(V) complexes emerge as an innovative and promising strategy for the oral treatment of VL.
Collapse
|
6
|
Zucca M, Savoia D. Current developments in the therapy of protozoan infections. THE OPEN MEDICINAL CHEMISTRY JOURNAL 2011; 5:4-10. [PMID: 21629507 PMCID: PMC3103884 DOI: 10.2174/1874104501105010004] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Revised: 05/25/2010] [Accepted: 06/20/2010] [Indexed: 12/03/2022]
Abstract
Protozoan parasites cause serious human and zoonotic infections, including life-threatening diseases such as malaria, African and American trypanosomiasis, and leishmaniasis. These diseases are no more common in the developed world, but together they still threaten about 40% of the world population (WHO estimates). Mortality and morbidity are high in developing countries, and the lack of vaccines makes chemotherapy the only suitable option. However, available antiparasitic drugs are hampered by more or less marked toxic side effects and by the emergence of drug resistance. As the main prevalence of parasitic diseases occurs in the poorest areas of the world, the interest of the pharmaceutical companies in the development of new drugs has been traditionally scarce. The establishment of public-private partnerships focused on tropical diseases is changing this situation, allowing the exploitation of the technological advances that took place during the past decade related to genomics, proteomics, and in silico drug discovery approaches. These techniques allowed the identification of new molecular targets that in some cases are shared by different parasites. In this review we outline the recent developments in the fields of protease and topoisomerase inhibitors, antimicrobial and cell-penetrating peptides, and RNA interference. We also report on the rapidly developing field of new vectors (micro and nano particles, mesoporous materials) that in some cases can cross host or parasite natural barriers and, by selectively delivering new or already in use drugs to the target site, minimize dosage and side effects.
Collapse
Affiliation(s)
- Mario Zucca
- Department of Clinical and Biological Sciences, University of Torino, Italy
| | | |
Collapse
|